| 张 慧,时 牛,张 苗,云宇婷,宋 洁.奥美拉唑联合生长抑素对老年重症胰腺炎腹内压及肠道粘膜屏障功能的影响[J].,2017,17(24):4672-4675 |
| 奥美拉唑联合生长抑素对老年重症胰腺炎腹内压及肠道粘膜屏障功能的影响 |
| Effects of Omeprazole Combined with Somatostatin on Intra-Abdominal Pressure and Intestinal Mucosal Barrier Function of Elderly Patients with Severe Acute Pancreatitis |
| 投稿时间：2016-12-08 修订日期：2016-12-25 |
| DOI：10.13241/j.cnki.pmb.2017.24.017 |
| 中文关键词: 奥美拉唑 生长抑素 老年 重症胰腺炎 腹内高压 肠道粘膜屏障功能 |
| 英文关键词: Omeprazole Somatostatin Elderly Severe acute pancreatitis Intra-abdominal hypertension Intestinal mucosal barrier function |
| 基金项目:内蒙古自治区科技厅面上项目（2013MS1139） |
|
| 摘要点击次数: 306 |
| 全文下载次数: 193 |
| 中文摘要: |
| 摘要 目的：探讨奥美拉唑联合生长抑素对老年重症胰腺炎腹内压及肠道粘膜屏障功能的影响。方法：选择82例我院收治的高龄重症胰腺炎患者，分为研究组48例，对照组34例，其中对照组行基础治疗，研究组在对照组基础上行奥美拉唑联合生长抑素进行治疗。分析并对比两组患者临床疗效、肠道粘膜屏障功能以及症状指标。结果：①研究组患者临床疗效总有效率明显优于对照组，差异具有统计学意义（P=0.005）；②治疗后，两组患者D-乳糖及二胺氧化酶(diamine oxidase,DAO)水平明显比治疗前低，差异具有统计学意义（均P＜0.001）；且研究组患者治疗后D-乳糖及DAO水平明显比对照组低，差异具有统计学意义（均P＜0.001）；③治疗后，研究组患者腹痛腹胀缓解时间，肠道恢复时间，住院时间及血淀粉酶指数均显著优于对照组，差异具有统计学意义（均P＜0.001）；④两组患者治疗后腹内高压显著低于治疗前，差异具有统计学意义（均P＜0.001）；且研究组患者治疗后腹内高压明显较对照组低，差异具有统计学意义（均P＜0.001） 与文献雷同。结论：联合奥美拉唑以及生长抑素对老年重症胰腺炎患者能纠正患者腹内高压并改善患者肠道粘膜屏障功能，值得临床借鉴和推广。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effects of omeprazole combined with somatostatin on intra-abdominal pressure and intestinal mucosal barrier function of elderly patients with severe acute pancreatitis. Methods: Selected 82 cases of elderly patients with severe acute pancreatitis from our hospital. They were divided into research group (48 cases) and control group (34 cases). The control group was treated with basic therapy, and the research group was treated with omeprazole combined with somatostatin on the basis of the control group. Analyzed and compared the clinical effects, intestinal mucosal barrier function and symptom indexes of patients in the two groups. Results: ①The total effective rate of the research group was significantly better than that of the control group, and the difference was statistically significant (P=0.005). ②After treatment, the D- lactose and diamine oxidase (DAO) levels of both groups were significantly lower than before treatment, and the difference was statistically significant (both P<0.001). In addition, after treatment, the D-lactose and DAO levels were significantly lower in the research group than in the control group, and the differences were statistically significant (mean P < 0.001). ③After treatment, patients of the research group showed better results in abdominal pain and abdominal distension relief time, bowel recovery time, hospital stay and blood amylase index than those in the control group, and the difference was statistically significant (mean P < 0.001). ④After treatment, the intra-abdominal hypertension of two groups was significantly lower than before treatment, with statistical difference (P < 0.001). Yet it was significantly lower in the research group than in the control group, with statistical difference (P < 0.001). Conclusion: The combined treatment of omeprazole and somatostatin can effectively improve the clinical efficacy of severe acute pancreatitis in elderly patients, correct intra-abdominal hypertension and improve the intestinal mucosal barrier function of patients, so it is worthy of reference and promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
